Thomas F Tedder

USPTO Granted Patents = 32 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 2.0

ph-index = 8

Forward Citations = 326(Granted Patents)

Location History:

S. Natick, MA (US) (1996 - 1998)
South Natick, MA (US) (1994 - 2001)
Wellesley, MA (US) (1991 - 2002)
Durham, NC (US) (1998 - 2022)

Company Filing History:

18 out of 1,207

Dana-farber-cancer Institute Inc.

Institut National De La Sante Et De La Recherche Medicale

patents

4. 1 out of 61

Assistance Publique - Hopitaux De Paris (aphp)

patents

where one patent can have more than one assignee

Years Active: 1991-2024

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12144859 - B cell depleting agent for the treatment of atherosclerosis (2024-11-19),

2. 11230598 - Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors (2022-01-25),

3. 10611999 - Methods of expanding and assessing B cells and using expanded B cells to treat disease (2020-04-07),

4. 10131875 - Regulatory B cells and their uses (2018-11-20),

5. 10017739 - Methods of expanding and assessing B cells and using expanded B cells to treat disease (2018-07-10),

6. 9913863 - Regulatory B cells and their uses (2018-03-13),

7. 9814740 - Methods and compositions combining immunotherapy with monocyte activation (2017-11-14),

8. 9669057 - Regulatory B cells and their uses (2017-06-06),

9. 9416187 - CD-20 specific antibodies and methods of employing same (2016-08-16),

10. 9260530 - Anti-CD19 antibodies and uses in B cell disorders (2016-02-16),

11. 8734792 - Reagents and treatment methods for autoimmune diseases (2014-05-27),

12. 8444973 - Anti-CD19 antibodies and uses in B cell disorders (2013-05-21),

13. 6921846 - Antibody production methods relating to disruption of peripheral tolerance in B lympho-cytes (2005-07-26),

14. 6451981 - Antibodies against lymphocyte-associated cell surface protein LAM-1 (2002-09-17),

15. 6274347 - Method of producing a cell surface bound lam-1 specific antibody (2001-08-14),

Title: The Innovative Contributions of Thomas F. Tedder in Atherosclerosis Research

Introduction: Thomas F. Tedder, a distinguished inventor based in Durham, NC, has made significant strides in the field of medical research, particularly in the study of atherosclerosis. With a remarkable portfolio of 32 patents, Tedder's innovations focus on novel therapeutic strategies targeting immune cells to combat this common cardiovascular condition.

Latest Patents: Among his latest groundbreaking patents is a B cell depleting agent for the treatment of atherosclerosis. This invention aims at preventing or treating atherosclerosis by utilizing a specialized B cell depleting agent. In addition, his research includes the development of antibodies and methods for depleting regulatory B cells, which can be used in combination with immune checkpoint inhibitors. These innovative methods provide new avenues for improving treatment options for individuals affected by atherosclerosis.

Career Highlights: Thomas F. Tedder has collaborated with prominent institutions such as Dana-Farber Cancer Institute and Duke University, where he has been instrumental in advancing research in immunotherapy and its applications in treating complex diseases. His dedication to the field has not only led to numerous patents but has also significantly impacted therapeutic strategies in clinical settings.

Collaborations: Throughout his career, Tedder has worked alongside notable colleagues, including Liang-Ji Zhou and Jonathan C. Poe. These partnerships have enriched his research and facilitated the development of innovative therapies that are crucial for advancing medical science.

Conclusion: Thomas F. Tedder stands out as a leading inventor whose contributions in the realm of atherosclerosis treatment highlight the importance of innovative approaches in the medical field. His extensive patent portfolio and collaborative efforts illustrate a commitment to research that may transform therapeutic options for patients suffering from cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.